Analysts expect Thermo Fisher Scientific Inc. (NYSE:TMO) to announce $6.02 billion in sales for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Thermo Fisher Scientific’s earnings. The highest sales estimate is $6.06 billion and the lowest is $5.97 billion. Thermo Fisher Scientific reported sales of $5.85 billion during the same quarter last year, which indicates a positive year over year growth rate of 2.9%. The company is scheduled to report its next quarterly earnings report on Wednesday, April 24th.
According to Zacks, analysts expect that Thermo Fisher Scientific will report full-year sales of $25.21 billion for the current fiscal year, with estimates ranging from $25.10 billion to $25.34 billion. For the next financial year, analysts anticipate that the firm will report sales of $26.56 billion, with estimates ranging from $26.22 billion to $27.07 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, January 30th. The medical research company reported $3.25 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.19 by $0.06. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 12.06%. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.26 billion. During the same quarter in the previous year, the firm earned $2.79 earnings per share. Thermo Fisher Scientific’s revenue was up 7.6% on a year-over-year basis.
Shares of NYSE TMO traded up $1.66 during midday trading on Friday, hitting $263.09. 2,371,785 shares of the company’s stock were exchanged, compared to its average volume of 1,748,235. Thermo Fisher Scientific has a 12-month low of $199.85 and a 12-month high of $266.18. The company has a current ratio of 1.73, a quick ratio of 1.23 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $104.31 billion, a price-to-earnings ratio of 23.66, a PEG ratio of 1.68 and a beta of 1.13.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 16th. Investors of record on Friday, March 15th will be given a $0.19 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $0.76 dividend on an annualized basis and a yield of 0.29%. Thermo Fisher Scientific’s payout ratio is presently 6.12%.
In other Thermo Fisher Scientific news, insider Gregory J. Herrema sold 3,299 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $263.05, for a total value of $867,801.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Gregory J. Herrema sold 5,400 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $251.51, for a total value of $1,358,154.00. Following the completion of the sale, the senior vice president now owns 31,846 shares of the company’s stock, valued at approximately $8,009,587.46. The disclosure for this sale can be found here. Insiders sold a total of 36,927 shares of company stock valued at $9,388,124 in the last 90 days. 0.49% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Calamos Advisors LLC lifted its position in Thermo Fisher Scientific by 5.4% in the fourth quarter. Calamos Advisors LLC now owns 132,462 shares of the medical research company’s stock valued at $29,644,000 after purchasing an additional 6,769 shares during the last quarter. Handelsbanken Fonder AB raised its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Handelsbanken Fonder AB now owns 367,354 shares of the medical research company’s stock valued at $82,210,000 after acquiring an additional 14,789 shares in the last quarter. Regent Investment Management LLC raised its holdings in shares of Thermo Fisher Scientific by 2.4% during the fourth quarter. Regent Investment Management LLC now owns 8,175 shares of the medical research company’s stock valued at $1,829,000 after acquiring an additional 190 shares in the last quarter. XR Securities LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $375,000. Finally, WealthPLAN Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 8.3% during the third quarter. WealthPLAN Partners LLC now owns 2,488 shares of the medical research company’s stock valued at $581,000 after acquiring an additional 190 shares in the last quarter. Hedge funds and other institutional investors own 87.11% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.